Evgen Pharma (GB:TCF) has released an update.
James Robert Kight has increased his stake in Theracryf PLC, with the acquisition of additional voting rights, now holding a total of 8.09647% or 34,600,000 voting rights. The notification was filed on July 17, 2024, after the threshold was crossed on the previous day. This move might suggest a growing confidence in the company’s prospects, which could interest investors tracking shareholder activity for investment insights.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
